河北医学Issue(12)：1956-1959,4.DOI:10.3969/j.issn.1006-6233.2015.12.007
莫西沙星联合呱拉西林钠／他唑巴坦对 COPD 并急性下呼吸道感染患者免疫球蛋白 PCT CRP 的影响
Influence of Moxifloxacin Combined Gung Piperacillin Sodium/Tazobactam on Immunoglobulin PCT and CRP of Patients with COPD Combined Acute Lower Respiratory Tract Infection
摘要
Abstract
Objective:To investigate the influence of moxifloxacin combined gung piperacillin sodium/tazobactam on immunoglobulin, PCT, and CRP of patients with COPD combined acute lower respiratory tract infections.Method:166 patients with COPD combined acute lower respiratory tract infections were randomly divided into 2 groups, each with 83 cases.Patients in control group were given gung piperacillin sodium/tazobactam combined levofloxacin, and patients in observation group were given gung piperacillin sodium/tazobactam combined moxifloxacin.Before and after treatment, immunoglobulin, PCT, and CRP of two groups were detected, and the bacterial clearance rate and adverse reactions were observed.Result: After treatment, IgA levels of two groups were significantly increased ( P<0.05), and IgA level of observation group was significantly higher than control group ( P<0.05);After treatment, IgM levels of two groups were significantly decreased (P<0.05), and IgA level of observation group was significantly lower than control group ( P<0.05) .After treatment, PCT, CR levels of two groups were significantly reduced ( P<0.05) , and PCT, CR levels of observation group were significantly lower than control group ( P<0.05) .The bacterial clearance rate of observation group was 93.1%, which was significantly higher than that of control group ( 80. 8%) ( P<0.05) .There were no serious adverse reactions in two groups.Conclusion:Moxifloxacin combined gung piperacillin sodium/tazobactam can effectively improve immunoglobulin and reduce the inflammatory re-sponse, with advantage of high bacterial clearance rate and no serious adverse reactions.关键词
莫西沙星/呱拉西林钠/他唑巴坦/COPD并急性下呼吸道感染Key words
Moxifloxacin/Gung piperacillin sodium/tazobactam/Patients with COPD combined acute lower respiratory tract infections引用本文复制引用
安晓洁,乜庆荣,邓赶飞..莫西沙星联合呱拉西林钠／他唑巴坦对 COPD 并急性下呼吸道感染患者免疫球蛋白 PCT CRP 的影响[J].河北医学,2015,(12):1956-1959,4.基金项目
北京科技厅项目， （）
